Studies of the DB-MSG - Dutch-Belgian Mycosis Study Group
page-template,page-template-full_width,page-template-full_width-php,page,page-id-16662,bridge-core-2.4.9,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,qode-child-theme-ver-1.0.0,qode-theme-ver-23.5,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.10.0,vc_responsive

Ongoing and future studies

Prospective studies


The AZOle Resistance MANagement (AZORMAN) study:


The AZORMAN study aims to evaluate if the use of a diagnostic PCR that detects mutations that confer resistance to voriconazole in the CYP51a of A. fumigatus can improve the management and outcome of patients infected with voriconazole resistant A.fumigatus.

Currently UMCU, EMC, UMCG, VUMC, LUMC MUMC and Radboud UMC are involved.

The PosaFlu Study:


Recent studies have shown that patients with very severe influenza are at significant risk of developing an invasive fungal infection with the fungus Aspergillus. The mortality in these patients is very high (51%).


The PosaFlu study is a randomized trial in which the value of posaconazole prophylaxis for the prevention of influenza associated aspergillus infections is investigated in patients admitted to the intensive care with influenza.


The study is enrolling patients in UZ Leuven, AZ Sint Jan in Bruges, UZ Gent in Ghent, Erasmus MC in Rotterdam, Radboud UMC in Nijmegen and UMCG in Groningen.

Retrospective or observational studies:

  • Diagnostic characteristics of recently CE certified aspergillus lateral flow devices for the diagnosis of invasive pulmonary aspergillosis in patients with hematological disease or patients admitted to the ICU (UZ Leuven, Erasmus MC Rotterdam, AZ St.-Jan Brugge, Radboud UMC, Nijmegen)
  • A study of the pharmacokinetis of posaconazole in patienst on ECMO (UZ Leuven, Erasmus MC Rotterdam, Radboud UMC, Nijmegen, UZ Gent)
  • A study of the pharmacokinetis of voriconazole in patienst receiving ECMO (Initiated by Isabel Spriet)
  • The impact of voriconazole resistance on the outcome of patients diagnosed with an invasive aspergillus infection. A multicenter study (initiated by Paul Verweij)
  • Study of the safety and efficacy of high dose posaconazole in patients infected with voriconazole resistant A.fumigatus. A multicenter study (initiated by Bart Rijnders)
  • Use of intermittent liposomal Amphotericin-B therapy (initiated by Mark de Boer)
  • Basilicum studie

This prospective multicentre case-control registration study in Dutch and Belgian ICUs will assess the difference in incidence and outcome of invasive pulmonary aspergillosis (IPA) in ICU patients with severe influenza compared with influenza-negative control patients with severe community-acquired pneumonia during the coming three influenza seasons (2017-2020). The study will further assess the differences in clinical characteristics and risk factors between influenza patients with and without invasive aspergillosis.

All consecutive patients aged 18 or older admitted to ICU during the inclusion period with respiratory distress due to influenza positive/negative community acquired pneumonia (CAP) will be included.